- Gilead (GILD) revenues have been declining every quarter for some time now.
- As long term and recent shareholders are well aware, this has had a very negative impact on the share price.
- Despite declining revenues from HCV sales, we believe that the company will eventually succeed in diversifying itself and finding new revenue streams.
Monday, May 15, 2017
Gilead Sciences (NASDAQ:GILD)
See the full Seeking Alpha article HERE